Bruce Gao1, Steven Lu2, Naeem Bhojani3, Kevin C Zorn3, Bilal Chughtai4, Dean Elterman5,6. 1. Division of Urology, Department of Surgery, University of Toronto, Room 503G, 149 College Street, Toronto, ON, M5T 1P5, Canada. 2. Cumming School of Medicine, University of Calgary, 3330 Hospital Dr NW, Calgary, AB, T2N 4N1, Canada. 3. Department of Surgery, University of Montreal (CHUM), 2900 Edouard Montpetit Blvd, Montreal, QC, H3T 1J4, Canada. 4. Department of Urology, Weill Cornell Medical College, 25 East 68th Street, Starr 9, New York, NY, 10065, USA. 5. Division of Urology, Department of Surgery, University of Toronto, Room 503G, 149 College Street, Toronto, ON, M5T 1P5, Canada. dean.elterman@uhn.ca. 6. UHN - Toronto Western Hospital, 399 Bathurst Street, MP-8-317, Toronto, ON, M5T2S8, Canada. dean.elterman@uhn.ca.
Abstract
PURPOSE OF REVIEW: Benign prostatic hyperplasia (BPH) is a common disease in men. A rapidly rising demand for safe and effective therapy for BPH has generated novel minimally invasive surgical treatments (MISTs). With multiple procedural options in the urology armamentarium for BPH therapy, we describe the current therapies and outcomes for office-based procedures for BPH including quality of life, voiding symptoms, and sexual function. RECENT FINDINGS: There are three FDA-approved MISTs (Rezūm, Urolift, and iTind) and three emerging MISTs for BPH. Preliminary data suggest improvement in voiding symptoms and quality of life while minimizing unwanted sexual side effects. Long term data is required on the durability and safety of MISTs for BPH. MISTs mark a paradigm shift in BPH management. Sandwiched between conservative medical management and conventional transurethral surgery, these novel technologies promise to combine efficacy approaching that of TURP while sparing the negative side effects. We envision a future where BPH can be diagnosed and treated in an office-based setting with a standard cystoscope in one procedure.
PURPOSE OF REVIEW: Benign prostatic hyperplasia (BPH) is a common disease in men. A rapidly rising demand for safe and effective therapy for BPH has generated novel minimally invasive surgical treatments (MISTs). With multiple procedural options in the urology armamentarium for BPH therapy, we describe the current therapies and outcomes for office-based procedures for BPH including quality of life, voiding symptoms, and sexual function. RECENT FINDINGS: There are three FDA-approved MISTs (Rezūm, Urolift, and iTind) and three emerging MISTs for BPH. Preliminary data suggest improvement in voiding symptoms and quality of life while minimizing unwanted sexual side effects. Long term data is required on the durability and safety of MISTs for BPH. MISTs mark a paradigm shift in BPH management. Sandwiched between conservative medical management and conventional transurethral surgery, these novel technologies promise to combine efficacy approaching that of TURP while sparing the negative side effects. We envision a future where BPH can be diagnosed and treated in an office-based setting with a standard cystoscope in one procedure.
Authors: Micheal F Darson; Erik E Alexander; Zvi J Schiffman; Michael Lewitton; Robert A Light; Mark A Sutton; Carlos Delgado-Rodriguez; Ricardo R Gonzalez Journal: Res Rep Urol Date: 2017-08-21
Authors: Brendan L Raizenne; David Bouhadana; Kevin C Zorn; Neil Barber; Peter Gilling; Steven Kaplan; Gopal Badlani; Bilal Chughtai; Dean Elterman; Naeem Bhojani Journal: World J Urol Date: 2022-08-30 Impact factor: 3.661